A comprehensive description of muscle symptoms associated with lipid-lowering drugs

被引:85
作者
Franc, S [1 ]
Dejager, S [1 ]
Bruckert, E [1 ]
Chauvenet, M [1 ]
Giral, P [1 ]
Turpin, E [1 ]
机构
[1] Assistance Publ Hop Paris, Hop La Pitie Salpetriere, Dept Endocrinol, F-75013 Paris, France
关键词
HMG-CoA-reductase inhibitors; fibrates; muscle side-effects; tendonopathies;
D O I
10.1023/B:CARD.0000015861.26111.ab
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A spectrum of disease from myalgia to rhabdomyolysis exists as classic side-effect of lipid-lowering treatment (LLT). While myopathy has generated considerable interest, mild musculo-skeletal symptoms are poorly assessed. Objective: To report on the muscular side-effects of LLT with a particular focus on the overlooked milder ones. Methods: Hyperlipidemic patients under LLT and complaining of muscle symptoms were asked to complete a self administered questionnaire. Among the 815 adult hyperlipidemic patients under LLT and referred to the cardiovascular prevention unit of La Pitie Hospital, 165 patients answered that they experienced, or had experienced, muscle symptoms which they attributed to the LLT. One hundred and thirty three of these completed and returned a self-administered questionnaire. Results: A clear chronological link between symptoms and the LLT was revealed, either because they appeared soon after drug initiation or because of an improvement after drug withdrawal. While cramps and stiffness were the most frequent symptoms, tendonitis-associated pain was surprisingly common, reported in almost half the cases. Pain was often diffuse with a focus on a given location, mainly lower limbs. 39% of patients had used analgesics for pain relief. Unpredictably, a majority of patients reported pain during rest and the lying position. In a number of cases, a family history of pain under LLT was revealed. Conclusion: The impact of these mild symptoms on daily activities might not be negligible in a subset of patients. The role and importance of a genetic background predisposing to low-grade myopathy deserves further investigation.
引用
收藏
页码:459 / 465
页数:7
相关论文
共 45 条
  • [1] [Anonymous], 1993, Am J Cardiol, V72, P1031
  • [2] Safety profile of atrovastatin-treated patients with low LDL-cholesterol levels
    Bakker-Arkema, RG
    Nawrocki, JW
    Black, DM
    [J]. ATHEROSCLEROSIS, 2000, 149 (01) : 123 - 129
  • [3] Frequency of creatine kinase elevation during treatment with fluvastatin
    Benghozi, R
    Bortolini, M
    Jia, Y
    Isaacsohn, JL
    Troendle, AJ
    Gonasun, L
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) : 231 - +
  • [4] Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
    Bertolini, S
    Bon, GB
    Campbell, LM
    Farnier, M
    Langan, J
    Mahla, G
    Pauciullo, P
    Sirtori, C
    Egros, F
    Fayyad, R
    Nawrocki, JW
    [J]. ATHEROSCLEROSIS, 1997, 130 (1-2) : 191 - 197
  • [5] Safety considerations for statins
    Bolego, C
    Baetta, R
    Bellosta, S
    Corsini, A
    Paoletti, R
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (06) : 637 - 644
  • [6] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS - 2-YEAR EFFICACY AND SAFETY FOLLOW-UP
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, CA
    FRANKLIN, FA
    GRILLO, RB
    HIGGINS, J
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (07) : 667 - 673
  • [7] Castelli W P, 1992, Ann Epidemiol, V2, P23, DOI 10.1016/1047-2797(92)90033-M
  • [8] Four cases of tendinopathy in patients on statin therapy
    Chazerain, P
    Hayem, G
    Hamza, S
    Best, C
    Ziza, JM
    [J]. JOINT BONE SPINE, 2001, 68 (05) : 430 - 433
  • [9] Clinically relevant differences between the statins: Implications for therapeutic selection
    Chong, PH
    Seeger, JD
    Franklin, C
    [J]. AMERICAN JOURNAL OF MEDICINE, 2001, 111 (05) : 390 - 400
  • [10] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3